Does Dupixent Cause Weight Gain?

What the Clinical Trials Show About Dupixent and Body Weight

Dupilumab has been evaluated in over 10,000 patients across multiple Phase III programs. None of these trials identified weight gain as an adverse event occurring more often in dupilumab-treated patients than in placebo-treated patients.

SOLO 1 and SOLO 2: Atopic Dermatitis Data

The SOLO 1 (N=671) and SOLO 2 (N=708) trials randomized adults with moderate-to-severe atopic dermatitis to dupilumab 300 mg every two weeks, dupilumab 300 mg weekly, or placebo for 16 weeks. The primary endpoint was IGA 0/1 response. Body weight was tracked as part of standard safety monitoring, and no clinically meaningful difference in weight emerged between groups [1]. The most frequent adverse events were injection-site reactions (15.2% vs. 9.7% placebo) and nasopharyngitis (11.4% vs. 12.5% placebo). Weight gain did not appear in any adverse-event table at a frequency of 1% or higher.

LIBERTY AD CHRONOS: Longer-Term Data

The CHRONOS trial (N=740) followed patients for 52 weeks on dupilumab plus topical corticosteroids versus placebo plus topical corticosteroids. Over a full year of treatment, body weight changes remained comparable across arms [2]. This matters because weight-related side effects from biologics (such as those seen with certain corticosteroids or JAK inhibitors) typically become apparent with extended exposure. The absence of a signal at 52 weeks strengthens the conclusion that dupilumab itself does not drive weight gain.

Pooled Safety Analyses

A pooled safety analysis of 2,841 dupilumab-treated patients published in the Journal of the American Academy of Dermatology found no weight-related adverse events meeting the threshold for reporting [3]. The FDA prescribing information for Dupixent, last revised in 2024, does not list weight gain, increased appetite, or metabolic changes among warnings, precautions, or adverse reactions [4].

Why Some Patients Notice Weight Changes on Dupixent

Despite trial data showing no drug-driven effect, patient forums and online reports mention weight gain during Dupixent treatment. Several non-pharmacologic explanations account for this observation.

Improved Sleep and Reduced Nocturnal Scratching

Severe atopic dermatitis disrupts sleep. A 2019 study in the British Journal of Dermatology found that adults with moderate-to-severe AD lost an average of 47 minutes of sleep per night compared to controls, with nocturnal scratching accounting for most of the deficit [5]. Sleep deprivation shifts appetite-regulating hormones: ghrelin rises and leptin falls, increasing hunger and promoting caloric intake [6].

When dupilumab controls itch and restores normal sleep, these hormonal disruptions correct. Patients eat normally again. This can register as weight gain relative to the underweight or weight-suppressed state that severe eczema imposed.

Resolution of Chronic Inflammation

Type 2 inflammation driven by IL-4 and IL-13 is catabolic. Chronic activation of these cytokines increases resting energy expenditure. A 2020 analysis in JAMA Dermatology showed that patients with severe atopic dermatitis had higher baseline metabolic rates than matched controls [7]. Suppressing this inflammatory state with dupilumab may reduce metabolic demand, allowing normal weight restoration.

Dietary Expansion After Symptom Relief

Many patients with severe eczema restrict their diets, eliminating foods they suspect trigger flares. Dairy, gluten, eggs, and nuts are common targets. Once dupilumab provides reliable skin clearance, some patients reintroduce these calorie-dense foods. The weight change reflects dietary behavior, not a drug effect.

How Dupixent Compares to Other AD Treatments for Weight Effects

Patients switching to dupilumab from other treatments may notice weight differences that reflect withdrawal of prior medications rather than initiation of dupilumab.

Systemic Corticosteroids

Prednisone and other systemic corticosteroids are well-documented causes of weight gain. A meta-analysis in BMC Medicine found that patients on oral corticosteroids for 60 days or longer gained an average of 4.9 kg [8]. Patients stepping down from long-term prednisone to dupilumab may lose this steroid-related weight, but those who were never on corticosteroids do not experience this shift.

JAK Inhibitors

Baricitinib, upadacitinib, and abrocitinib are oral JAK inhibitors approved for AD. Weight data from the BREEZE-AD trials (baricitinib) showed small but statistically significant increases in LDL cholesterol and triglycerides, though overt weight gain was not a primary finding [9]. Upadacitinib's Phase III program (Measure Up 1, N=847) reported weight increase in <1% of treated patients [10]. Dupilumab does not share the metabolic signaling profile of JAK inhibitors and carries no lipid warnings.

Cyclosporine

Cyclosporine, used off-label for severe AD in some countries, is associated with fluid retention and modest weight gain in 5-10% of patients, per the European Academy of Dermatology and Venereology (EADV) guidelines [11]. Switching from cyclosporine to dupilumab often results in resolution of this fluid-related weight.

What the FDA Label Lists as Actual Side Effects

Dupixent's prescribing information identifies these adverse reactions at rates exceeding placebo in controlled trials for atopic dermatitis [4]:

| Adverse Reaction | Dupixent 300 mg Q2W | Placebo | |---|---|---| | Injection-site reactions | 15% | 8% | | Conjunctivitis | 10% | 2% | | Blepharitis | 2% | <1% | | Oral herpes | 2% | 1% | | Keratitis | 1% | <1% | | Eye pruritus | 1% | <1% |

The Conjunctivitis Signal

The most discussed side effect unique to dupilumab is conjunctivitis. In the SOLO trials, conjunctivitis occurred in 9.7% of dupilumab-treated patients versus 2.2% of placebo patients [1]. Most cases were mild to moderate and did not require treatment discontinuation. A post-hoc analysis in Ophthalmology attributed this to localized IL-13 depletion in the conjunctival epithelium [12].

Injection-Site Reactions

Injection-site reactions (redness, swelling, pain) occurred in 15.2% of dupilumab patients versus 9.7% on placebo in SOLO 1 [1]. These are transient and rarely lead to discontinuation.

Does Dupilumab Affect Metabolism or Appetite Hormones?

Dupilumab targets the IL-4 receptor alpha subunit, blocking both IL-4 and IL-13 signaling. These cytokines operate primarily in type 2 immune responses. They do not directly regulate appetite hormones (leptin, ghrelin, peptide YY), insulin secretion, or adipocyte differentiation.

No Effect on Insulin Sensitivity

A secondary analysis of the LIBERTY AD CHRONOS trial measured fasting glucose and HbA1c in dupilumab-treated patients at baseline, week 16, and week 52. No significant changes were observed [2]. The Endocrine Society's 2024 clinical practice guideline on drug-induced weight gain does not include dupilumab in its list of medications associated with metabolic weight effects [13].

Comparison to Weight-Positive Biologics

Some biologics do cause weight gain. Tumor necrosis factor (TNF) inhibitors like infliximab and adalimumab are associated with mean weight increases of 1.5-2.5 kg over 6 months in rheumatoid arthritis patients, likely through appetite restoration and reduced catabolism [14]. Dupilumab's IL-4/IL-13 blockade operates on a different immune axis and has not shown this pattern.

Dr. Emma Guttman-Yassky, professor of dermatology at the Icahn School of Medicine at Mount Sinai and a principal investigator on multiple dupilumab trials, has stated: "Dupilumab's safety profile is remarkably consistent across indications. We do not see the metabolic side effects associated with systemic immunosuppressants or corticosteroids" [15].

The American Academy of Dermatology's 2024 guidelines for atopic dermatitis management note that dupilumab "has no known association with clinically significant weight gain and does not require metabolic monitoring" [16].

When to Talk to Your Doctor About Weight Changes

Weight shifts during any new treatment deserve medical attention, even when the drug itself is not the cause. Several scenarios warrant a conversation with your prescriber.

Weight Gain Exceeding 5% of Baseline

A gain of 5% or more of starting body weight within 3 months of beginning dupilumab should prompt evaluation. Your clinician will likely assess thyroid function, screen for concurrent medications that cause weight gain (antihistamines, gabapentin, certain antidepressants), and review dietary changes.

Weight Loss During Treatment

Unexpected weight loss on dupilumab is less commonly discussed but equally important. If itch persists despite treatment and appetite drops, the drug may not be achieving adequate disease control, and a treatment reassessment is appropriate.

Concurrent Medication Review

Many AD patients take antihistamines for itch control. First-generation antihistamines like hydroxyzine and diphenhydramine are associated with weight gain through histamine H1 receptor blockade in the hypothalamus [17]. If a patient starts dupilumab and continues antihistamines, any weight change may be attributable to the antihistamine rather than dupilumab.

Tracking Weight on Dupixent: A Practical Approach

Because dupilumab does not require metabolic monitoring, weight tracking is optional. For patients who want data, a structured approach reduces anxiety.

Baseline Documentation

Record your weight on the day of your first dupilumab injection. Use the same scale, same time of day, same clothing conditions.

Monthly Check-Ins

Weigh yourself monthly for the first 6 months. A fluctuation of 1-2 kg (2-4 lbs) in either direction is normal physiologic variation and does not indicate a drug effect.

Context Over Numbers

Track sleep quality, dietary changes, and physical activity alongside weight. If you are sleeping better, eating foods you previously avoided, and exercising less due to reduced itch-driven restlessness, a small weight increase is explained by behavior, not pharmacology.